Bristol-Myers Squibb

Investing Hints From the Newest Forbes Billionaires

When it comes to getting rich, the best textbook may be Forbes' billionaires list. After all, who better to show the right steps to financial freedom than the world's most successful men and women? And, with a new list fresh off the presses, what better time could there be to reap their wisdom?

6 Stocks and 1 Fund That Have Already Doubled This Year

The S&P 500 soared 12% during the first three months of 2012, and the tech-heavy Nasdaq managed a nearly 19% spurt. Those are good numbers even for a whole year -- but these seven investments beat the indexes by huge margins.

A Simple Strategy to Boost Your Returns

Options: It's a word that makes you shiver with fear or salivate at opportunity. In fact, there's one options strategy that's almost certain to add some extra money to your portfolio over time, without adding lots of risk. It's the technique known as writing covered calls, and it's perfect for times like this.

The Dark Cloud Over Growing Antidepressant Prescriptions

They call it the Great "Recession," but there's no question that these are depressing times. And doctors are writing scripts for antidepressants at an alarming rate -- especially given that many of these doctors aren't psychiatrists. What are the effects on patients who haven't been properly screened?

Three Favorite Stocks of Wealthy Investors

According to a recent survey, wealthy U.S. investors are the most optimistic than they've been in months. And of those looking to invest more in the stock market, they have several clear ideas on where they'd like to place their bets.

Top-Selling Drugs About to Lose Patent Protection

The pharmaceutical industry is ready to fall off a cliff -- a "patent cliff." Over the next few years, some of the world's most popular and lucrative medicines will go off patent, and generic competition will siphon an estimated quarter of a trillion dollars from drugmakers' bottom lines.

Pfizer Joins Other Pharmas in Giving a Cautious Outlook

Pfizer reported fourth-quarter earnings on Tuesday that nearly quadrupled from a year ago as revenue rose 6%. But it also lowered its sales guidance for 2012, due to some of its bestselling drugs going off patent. What's ahead for the world's biggest drugmaker:

Another Cancer-Drug Failure Highlights Difficulties Facing Pharmas

Sanofi-Aventis announced its cancer drug candidate iniparib failed in a late-stage clinical trial. Other pharmaceutical companies have also experienced recent setbacks as they scramble to bolster their pipelines ahead of the patent cliff, when they will be forced to compete with cheaper generics.

As Diabetes Explodes, Big Pharma Is Gearing Up

Diabetes is a growing global scourge, but for Big Pharma it's more of a lifesaver -- and many drugmakers are cranking up their research efforts. After all, many existing drugs will soon be losing their patents, and diabetes could be a $55 billion market by 2019.

AstraZeneca's Brilinta Fails to Win FDA Approval

The FDA disappointed AstraZeneca and its investors by not approving its heart drug Brilinta, a blood-thinner that the company -- facing a severe patent cliff -- has high hopes for. If approved, it could be a multibillion-dollar blockbuster. But the FDA wants to see more analyses of results from a major study.

AstraZeneca's Heart Drug Brilinta: The FDA Is Ready to Rule

More than a year after AstraZeneca filed for approval, the FDA will make its decision on Thursday. A large study showed the blood thinner worked better than Plavix for treating acute coronary syndrome -- but approval isn't a sure thing, due in part to some oddities in the study's results.

Growing Interest
in Achillion's Hepatitis Drugs

At a liver disease conference in Boston, one highlight is expected to be reports from Achillion about its new hepatitis C treatments, especially ACH-1625. The buzz is growing that the little biotech is attracting the attention of some players in Big Pharma.